rs12123821 — FLG Filaggrin skin barrier variant

Common regulatory variant in the FLG locus associated with impaired skin barrier function and substantially elevated risk for atopic dermatitis (eczema)

See your personal result for FLG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FLG rs12123821 — Skin Barrier, Eczema, and the Atopic Cascade

Your skin is not just a passive envelope — it is an active immune barrier, and filaggrin is one of its most critical structural proteins. FLG (filaggrin) is produced in huge quantities in the outermost layers of the epidermis, where it aggregates keratin filaments11 aggregates keratin filaments
Filaggrin cross-links the keratin cytoskeleton into the dense protein mesh that gives the cornified envelope its mechanical strength and is then enzymatically broken down into natural moisturizing factor (NMF) — the collection of amino acids and derivatives that keeps the stratum corneum hydrated and acidic. The rs12123821 variant lies in the regulatory region of the FLG locus on chromosome 1q21, and the T allele tags a haplotype associated with reduced filaggrin expression. When filaggrin is in short supply, the skin barrier leaks.

The Mechanism

A well-functioning filaggrin layer does two things simultaneously: it locks water in and keeps allergens and microorganisms out. FLG variants that reduce filaggrin expression disrupt both functions in parallel. Transepidermal water loss (TEWL22 TEWL
A standardized measurement of water vapor flux through the skin surface; elevated TEWL means the barrier is leaking water and is correspondingly more permeable to external insults) rises measurably in FLG variant carriers even before any visible eczema appears. At the same time, the disrupted tight junction zone allows environmental allergens — house dust mite proteins, pollen fragments, pet dander, food proteins — to breach the stratum corneum and encounter cutaneous dendritic cells in a pro-inflammatory context rather than the tolerogenic context of the gut. This epicutaneous sensitization route33 epicutaneous sensitization route
Allergen encountered through the skin primes a TH2 immune response, whereas the same allergen ingested orally typically promotes tolerance is now understood as the primary mechanism initiating the atopic cascade.

The rs12123821 T allele is a common, low-frequency variant (about 4.8% in Europeans, essentially absent in East Asians) that tags this reduced-expression haplotype. Unlike the rare high-penetrance FLG loss-of-function coding mutations (R501X, 2282del4) that completely abolish filaggrin production, rs12123821 represents a more moderate graded impairment — contributing to population-level eczema risk with a well-powered OR of 1.40 in the largest available study.

The Evidence

The primary evidence comes from the largest atopic dermatitis GWAS meta-analysis published to date. Budu-Aggrey et al. (Nature Communications, 2023)44 Budu-Aggrey et al. (Nature Communications, 2023)
European and multi-ancestry GWAS meta-analysis of atopic dermatitis highlights importance of systemic immune regulation; Ashley Budu-Aggrey et al., Nat Commun 14:6172, 2023 assembled a discovery cohort of 1,086,394 individuals across 29 studies and a replication cohort of over 3.6 million through 23andMe. At the FLG locus, rs12123821 reached OR=1.40 (95% CI 1.35–1.45, P=4.05×10⁻⁹⁰) in European discovery and OR=1.27 (P=1.4×10⁻²²⁸) in the 23andMe replication — some of the most statistically robust findings in complex disease genetics. A total of 91 AD loci were identified; the FLG region remained the single largest common-variant effect.

The mechanistic link was established in the landmark Palmer et al. (Nature Genetics, 2006)55 Palmer et al. (Nature Genetics, 2006)
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis; CA Palmer, IJ McLean et al., Nat Genet 38(4):441–446 study, which showed filaggrin variants "establish a key role for impaired skin barrier function in the development of atopic disease" and that approximately 9% of Europeans carry a FLG loss-of-function allele. Subsequent infant cohort studies quantified the early timeline: Flohr et al. (2011)66 Flohr et al. (2011) showed FLG variant carriers already had substantially elevated TEWL (21.59 vs 11.24 g m⁻² h⁻¹) and 4.26-fold eczema odds at just 3 months of age, and the PreventADALL cohort (2022)77 PreventADALL cohort (2022) (1,836 infants) confirmed OR=2.89 for early eczema onset. The downstream consequence reaches beyond eczema: the Venkataraman et al. (2014)88 Venkataraman et al. (2014) Isle of Wight cohort demonstrated that FLG loss-of-function mutations carry striking food allergy risk (OR=31.46 at age 10), mediated entirely through the prior eczema state and epicutaneous sensitization.

Practical Actions

The core strategy for FLG variant carriers has two components: reinforcing the deficient barrier from outside, and reducing exposure to triggers that exploit the barrier gap. High-lipid emollients — particularly those formulated with ceramides, the lipid class that fills the intercellular spaces of the stratum corneum — can partially compensate for reduced filaggrin-derived NMF. Frequency and coverage matter: casual daily moisturizing is not equivalent to therapeutic barrier maintenance. Environmental allergen mitigation (house dust mite covers, avoidance of certain preservatives such as methylisothiazolinone in skincare products) is particularly valuable for FLG variant carriers because their barrier lets these sensitizers through more readily. Proactively managing known eczema flare triggers — rather than reacting after the fact — is the evidence-based posture for this genotype.

Interactions

FLG variant status interacts with environmental allergen burden: the same FLG haplotype that increases eczema risk in a high-allergen household may have attenuated effects in a lower-allergen environment, suggesting that allergen exposure amplifies the genetic risk. Within the atopic cascade, rs12123821 T-allele carriers who develop eczema early face substantially higher risk for subsequent asthma and food allergy compared to individuals whose eczema has non-FLG genetic drivers — because FLG-driven eczema specifically creates the epicutaneous sensitization route. Related FLG locus variants rs61816761 and rs558269137 encode the classical high-penetrance loss-of-function coding mutations (R501X and 2282del4) with larger individual effect sizes but much lower population frequencies; rs12123821 captures additional population-level risk at the same locus via regulatory architecture.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard Skin Barrier Normal

No FLG risk allele; standard filaggrin expression and population-average eczema risk

You carry two copies of the C allele at rs12123821, meaning you do not carry the FLG regulatory risk haplotype at this locus. Your filaggrin expression is at population-average levels, and your genetic risk for atopic dermatitis from this variant is not elevated. This is the predominant genotype — approximately 92–93% of people globally, and about 91% of Europeans, share this genotype. East Asian populations have near-universal CC frequency (essentially 100%).

CT Reduced Barrier Function Intermediate

One copy of the FLG risk allele; moderately impaired skin barrier and elevated eczema risk

The rs12123821 T allele tags a regulatory haplotype in the FLG gene region on chromosome 1q21 that reduces filaggrin expression. Filaggrin is the principal protein responsible for the moisture-retaining and barrier-sealing properties of the stratum corneum — the outermost skin layer. Reduced filaggrin results in elevated transepidermal water loss (TEWL), a measurably drier and more permeable skin surface, and increased penetration of allergens and irritants. Infant studies show that FLG variant carriers already have higher TEWL and elevated eczema odds by age 3 months, before clinical disease has fully manifested.

The 40% elevated eczema risk from a single T allele is substantial in the context of complex disease genetics. The absolute risk depends on your baseline: in Western European populations with overall atopic dermatitis prevalence of 15–20% in children, a 40% relative increase translates to a clinically meaningful difference in probability of developing eczema. Because FLG-variant eczema specifically creates epicutaneous allergen sensitization, managing it early reduces downstream food allergy and asthma risk.

TT Significantly Impaired Barrier High Risk

Two copies of the FLG risk allele; substantially impaired skin barrier with markedly elevated eczema and atopic disease risk

Homozygous TT individuals carry the FLG regulatory risk haplotype on both chromosomes, effectively halving filaggrin expression from a baseline that is already the lowest of the three genotype groups. Filaggrin deficiency at this level results in measurably elevated TEWL from early infancy — infant cohort studies show FLG variant carriers have TEWL nearly double that of non-carriers, with the effect present even before clinical eczema manifests. The compromised stratum corneum acts as a continuous leaky membrane: allergens, environmental toxins, and microbial products penetrate the skin in quantities that would be blocked by a filaggrin-replete barrier.

The downstream consequences are significant. FLG-driven eczema specifically generates epicutaneous allergen sensitization — a route that primes TH2 immunity and IgE production. Isle of Wight cohort data showed children with FLG loss-of-function mutations had strikingly elevated food allergy risk (OR=31.46 at age 10), operating entirely through the eczema pathway. TT carriers at this variant have substantially elevated probability of traversing the full atopic cascade: eczema in infancy or early childhood, sensitization to food proteins and aeroallergens through the disrupted barrier, and subsequent development of asthma and/or allergic rhinitis.

Therapeutic approach at this genotype is proactive and sustained, not reactive. Waiting for flares and treating them episodically leaves the sensitization window open; the goal is continuous barrier maintenance that prevents allergen penetration in the first place.